top of page
All Stakeholders 2017

Action 31: Work together in a coordinated and transparent manner to ensure paediatric formulations are rapidly registered, introduced, and made widely available at an affordable cost in a maximum of high-burden countries.

Action 32: Identify alternative incentives and innovative financial mechanisms for the research, development and sustained supply of paediatric formulations, including advanced purchase commitments or other interventions.

Action 33: In addition to paediatric drugs and formulations in the pipeline, support the greater use of currently available WHO prequalified diagnostics and drugs in the WHO recommended regimens.



bottom of page